help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2272
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/4/1402    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Gool, S. A.
Right arrow Articles by Wit, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Gool, S. A.
Right arrow Articles by Wit, J. M.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Pediatric Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 4 1402-1408
Copyright © 2007 by The Endocrine Society

Final Height Outcome after Three Years of Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Short Adolescents with Relatively Early Puberty

Sandy A. van Gool, Gerdine A. Kamp, Hanneke Visser-van Balen, Dick Mul, Johan J. J. Waelkens, Maarten Jansen, Liesbeth Verhoeven-Wind, Henriëtte A. Delemarre-van de Waal, Sabine M. P. F. de Muinck Keizer-Schrama, Geraline Leusink, Jan C. Roos and Jan M. Wit

Department of Pediatrics (S.A.v.G., J.M.W.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Tergooi Hospital (G.A.K.), 1250 CA Blaricum, The Netherlands; Department of Developmental Psychology (H.V.-v.B.), Utrecht University, 3508 TA Utrecht, The Netherlands; Subdivision Endocrinology (D.M., S.M.P.F.d.M.K.-S.), Erasmus University Medical Center/Sophia Children’s Hospital, 3015 GJ Rotterdam, The Netherlands; Catharina Hospital (J.J.J.W.), 5623 EJ Eindhoven, The Netherlands; University Medical Center Utrecht/Wilhelmina Children’s Hospital (M.J., L.V.-W., H.V.-v.B.), 3508 AB Utrecht, The Netherlands; Departments of Pediatrics (H.A.D.-v.d.W.) and Radiology (J.C.R.), VU University Medical Center, 1007 MB Amsterdam, The Netherlands; and Diagnostic Center Eindhoven (G.L.), 5611 NE Eindhoven, The Netherlands

Address all correspondence and requests for reprints to: Dr. S. A. van Gool, Leiden University Medical Center, Department of Pediatrics, J6-S, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: s.van_gool{at}lumc.nl.

Objective: Our objective was to assess final height (FH) and adverse effects of combined GH and GnRH agonist (GnRHa) treatment in short adolescents born small for gestational age or with normal birth size (idiopathic short stature).

Design and Patients: Thirty-two adolescents with Tanner stage 2–3, age and bone age (BA) less than 12 yr for girls or less than 13 yr for boys, height SD score (SDS) less than –2.0 SDS or between –1.0 and –2.0 SDS plus a predicted adult height (PAH0) less than –2.0 SDS were randomly allocated to receive GH plus GnRHa (n = 17) or no treatment (n = 15) for 3 yr. FH was assessed at the age of 18 yr or older in girls or 19 yr or older in boys.

Results: FH was not different between treatment and control groups. Treated children had a larger height gain (FH – PAH0) than controls: 4.4 (4.9) and –0.5 (6.4) cm, respectively (P < 0.05). FH was higher than PAH0 in 76 and 60% of treated and control subjects, respectively. During follow-up, 50% of the predicted height gain at treatment withdrawal was lost, resulting in a mean gain of 4.9 cm (range, –4.0 to 12.3 cm) compared with controls. Treatment did not affect body mass index or hip bone mineral density. Mean lumbar spine bone mineral density and bone mineral apparent density tended to be lower in treated boys, albeit statistically not significant.

Conclusion: Given the expensive and intensive treatment regimen, its modest height gain results, and the possible adverse effect on peak bone mineralization in males, GH plus GnRHa cannot be considered routine treatment for children with idiopathic short stature or persistent short stature after being born small for gestational age.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society